Literature DB >> 27488930

Persistence of rubella and mumps antibodies, following changes in the recommended age for the second dose of MMR vaccine in Portugal.

G Gonçalves1, J Frade1, M S J Nascimento2, J R Mesquita3, C Nunes4.   

Abstract

In Portugal, the recommended age for the second dose of MMR (MMR2) was changed from 10-13 years to 5-6 years for those born in 1994 and afterwards. This study aimed to assess if MMR schedule and time elapsed from the last dose are associated with the concentration of rubella and mumps IgG antibodies. Three Portuguese birth cohorts (convenience samples) were selected for this study (66, 59 and 41 participants born respectively in 1990-1993, 1994-1995 and 2001-2003). Geometric mean concentrations (GMC) for mumps IgG were respectively 36, 30 and 38 RU/ml (P = 0·236) and for rubella IgG were 18, 20 and 17 IU/ml (P = 0·641). For both specific antibodies, no differences were observed with time since MMR2. Receiving MMR2 at 5-6 or 10-13 years was not associated with concentration of both antibodies. The GMC of rubella IgG was lower in males (P = 0·029). Taking into account previous evidence and the logistics needed to change vaccination schedules, it seems reasonable that sustaining very high coverage with two doses of MMR is currently the most pragmatic way to control mumps and rubella rather than any changes to the schedule.

Entities:  

Keywords:  Immuno-epidemiology; mumps; rubella; vaccination (immunization)

Mesh:

Substances:

Year:  2016        PMID: 27488930      PMCID: PMC9150187          DOI: 10.1017/S0950268816001655

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  19 in total

1.  Outbreak of mumps associated with poor vaccine efficacy - Oporto Portugal 1996.

Authors:  G Goncalves; A De Araujo; M.L. Monteiro Cardoso
Journal:  Euro Surveill       Date:  1998-12

2.  Long-term persistence of antibodies after one or two doses of MMR-vaccine.

Authors:  Corinne Vandermeulen; Roelants Mathieu; Leroux-Roels Geert; Van Damme Pierre; Hoppenbrouwers Karel
Journal:  Vaccine       Date:  2007-07-26       Impact factor: 3.641

3.  Assessing mumps outbreak risk in highly vaccinated populations using spatial seroprevalence data.

Authors:  Steven Abrams; Philippe Beutels; Niel Hens
Journal:  Am J Epidemiol       Date:  2014-02-25       Impact factor: 4.897

Review 4.  The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.

Authors:  K J Bart; W A Orenstein; A R Hinman
Journal:  Dev Biol Stand       Date:  1986

5.  Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.

Authors:  Irja Davidkin; Sari Jokinen; Mia Broman; Pauli Leinikki; Heikki Peltola
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

Review 6.  Measles elimination: progress, challenges and implications for rubella control.

Authors:  Felicity T Cutts; Justin Lessler; Charlotte J E Metcalf
Journal:  Expert Rev Vaccines       Date:  2013-08       Impact factor: 5.217

7.  Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine.

Authors:  Charles W LeBaron; Bagher Forghani; Carol Beck; Cedric Brown; Daoling Bi; Cynthia Cossen; Bradley J Sullivan
Journal:  J Infect Dis       Date:  2009-02-15       Impact factor: 5.226

Review 8.  [Congenital rubella. Still with us].

Authors:  M J Saldanha; A Azevedo
Journal:  Acta Med Port       Date:  1995-05

9.  Models of strategies for control of rubella and congenital rubella syndrome-a 40 year experience from Australia.

Authors:  Zhanhai Gao; James G Wood; Margaret A Burgess; Robert I Menzies; Peter B McIntyre; C Raina MacIntyre
Journal:  Vaccine       Date:  2012-11-26       Impact factor: 3.641

10.  Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity.

Authors:  Christina Poethko-Müller; Annette Mankertz
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

View more
  1 in total

1.  Rubella antibodies in cord blood sera in Portugal: association with maternal age and vaccination status.

Authors:  J Frade; C Nunes; J R Mesquita; M São José Nascimento; G Gonçalves
Journal:  Epidemiol Infect       Date:  2018-02-20       Impact factor: 4.434

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.